# Oligonucleotide Synthesis Market

> Oligonucleotide Synthesis Market Research Report: Size, Share, Trend Analysis By Product Type (DNA Oligonucleotides, RNA Oligonucleotides, Modified Oligonucleotides, ASO Oligonucleotides), By Applications (Diagnostics, Therapeutics, Research Development, Gene Synthesis), By End Users (Pharmaceutical Companies, Biotechnology Companies, Academic Research Institutions, Contract Research Organizations), By Technology (Solid-Phase Synthesis, Liquid-Phase Synthesis, Microarray Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 11.32%
- **2025:** USD 4.10 Billion
- **2035:** USD 12.68 Billion
- **Key Players:** Thermo Fisher Scientific, Agilent Technologies, Integrated DNA Technologies (IDT), Eurofins Genomics, GenScript Biotech, LGC Biosearch Technologies, Twist Bioscience, Ajinomoto Bio-Pharma

**Report ID:** MRFR/LS/1721-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/oligonucleotide-synthesis-market-2337

---

## Market Summary

The Global Oligonucleotide Synthesis Market size was valued at USD 12.38 Billion in 2024, and the market is projected to grow from USD 14.27 Billion in 2025 to USD 58.89 Billion by 2035, registering a CAGR of 15.2% during the forecast period 2025–2035. North America led the market with over 45.23% share, generating around USD 5.6 Billion in revenue.
 
Growing adoption of personalized medicine, genomics research, and RNA-based therapeutics is a major growth driver for the Oligonucleotide Synthesis Industry, increasing demand for custom oligonucleotides in diagnostics, drug discovery, gene therapies, and advanced molecular biology applications across healthcare and biotechnology sectors.
 
According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2022, significantly accelerating demand for precision diagnostics and targeted therapies, thereby supporting increased utilization of synthetic oligonucleotides in genomics, molecular testing, and personalized medicine development worldwide.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Expanding nucleic acid therapeutics pipeline | ~22% | Global | Long-term (≥4 yr) | [3] |
| Enzymatic synthesis platform adoption | ~18% | North America, Europe | Medium-term (2–4 yr) | [5] |
| CRISPR guide RNA production demand | ~16% | Global | Medium-term (2–4 yr) | [7] |
| Government research funding (NIH, ERC) | ~14% | North America, Europe | Short-term (≤2 yr) | [2] |
| Pharmaceutical outsourcing to CDMOs | ~12% | Asia-Pacific, North America | Medium-term (2–4 yr) | [6] |
| Molecular diagnostics expansion | ~10% | Global | Short-term (≤2 yr) | [9] |
| Environmental regulation of legacy reagents | ~8% | Europe, North America | Long-term (≥4 yr) | [10] |

### Expanding Nucleic Acid Therapeutics Pipeline

With 14 different ASO medications receiving regulatory clearance through 2024, the antisense oligonucleotide (ASO) therapy category is a key component of the market. GMP-grade oligo demand is rising dramatically because of late-stage [clinical trials](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787) for diseases like Huntington's disease and congenital transthyretin amyloidosis [[3]](https://www.liebertpub.com/journal/nat). Ionis Pharmaceuticals said that it had more than 40 ongoing clinical projects in the works, many of which call for multi-kilogram synthesis batches. Ten years ago, this scale just did not exist. The Oligonucleotide Synthesis Market is under constant procurement pressure due to the FDA's fast approval pathway for rare-disease oligonucleotide candidates, which significantly shortens development durations [[8]](https://www.alnylam.com/pipeline).

### Enzymatic Synthesis Platform Adoption

By eliminating the requirement for phosphoramidite reagents and organic solvents, enzymatic DNA/RNA strand manufacturing technology reduces the amount of hazardous waste produced by an estimated 85% each synthesis cycle [[5]](https://www.dnascript.com). In order to commercialize benchtop enzymatic synthesizers, leading pioneers like DNA Script and Nuclera have successfully raised millions of dollars in venture capital, hastening the decentralization of clinical facilities and research labs. Benchtop enzymatic systems are quickly taking over the rapid-turnaround research market for custom oligos up to 120-mers, while classic chemical phosphoramidite methods continue to dominate commercial long-mer and large-scale manufacture due to established per-cycle coupling efficiency [[5]](https://www.dnascript.com)[[11]](https://www.nuclera.com).

### CRISPR Guide RNA Production Demand

Each CRISPR-based therapeutic program requires hundreds of unique guide RNA sequences during screening, with lead candidates needing GMP-grade production at milligram-to-gram scale [[7]](https://www.nature.com/nbt). The approval of Casgevy (exa-cel) in late 2023 for sickle cell disease validated the commercial pathway, and at least 65 CRISPR clinical trials were active globally by Q3 2024 [[12]](https://clinicaltrials.gov). This expanding pipeline is a direct multiplier for custom oligo manufacturing volumes across the Oligonucleotide Synthesis Market.

### Government Research Funding Programs

The NIH allocated USD 16.4 million specifically to RNA-focused synthesis innovation in its 2024 grant cycle, while the European Research Council channeled EUR 120 million into nucleic acid chemistry synthesis and delivery research under Horizon Europe [[2]](https://www.nih.gov)[[13]](https://research-and-innovation.ec.europa.eu). These public investments de-risk early-stage platform development and accelerate the transition from bench-scale to commercial-scale DNA/RNA strand production.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High cost of GMP-grade synthesis | ~–18% | Global | Medium-term (2–4 yr) | [14] |
| Intellectual property barriers around modified nucleotides | ~–15% | North America, Europe | Long-term (≥4 yr) | [15] |
| Quality consistency at the kilogram scale | ~–14% | Global | Medium-term (2–4 yr) | [6] |
| Skilled workforce shortages in oligo chemistry | ~–12% | Asia-Pacific, MEA | Short-term (≤2 yr) | [16] |
| Regulatory uncertainty for novel modifications | ~–10% | Global | Long-term (≥4 yr) | [17] |

### High Cost of GMP-Grade Custom Oligo Manufacturing

Therapeutic-grade oligonucleotide production costs remain 15–20× higher than research-grade equivalents, with GMP synthesis of a single antisense oligonucleotide therapy candidate running USD 50,000–200,000 per gram depending on sequence length and modification complexity [[14]](https://www.avecia.com). This pricing reality restricts smaller biotech firms from advancing clinical programs and concentrates demand among well-capitalized sponsors, limiting the addressable customer base for the Oligonucleotide Synthesis Market.

### Intellectual Property Barriers

Although typical 2'-O-methyl linkages, phosphorothioate modifications, and basic phosphoramidite chemistry have mostly entered the public domain, complicated patent thickets still exist around targeted ligand conjugations and private next-generation alterations. For younger contract manufacturers, multi-layered intellectual property landscapes encompassing targeted GalNAc multimer designs, specific lipid nanoparticles, and advanced endosomal escape modifications generate substantial licensing obstacles. These specific intellectual property restrictions postpone the wider introduction of rival low-cost nucleic acid chemistry synthesis possibilities and slow down the erosion of generic costs.

### Quality Consistency at Scale

Scaling oligo production from milligram research batches to multi-kilogram GMP lots introduces purity and truncation challenges that increase failure rates by an estimated 6–10% per production run [[6]](https://www.genscript.com/investor-relations). Inconsistent coupling efficiencies at longer sequence lengths remain a technical bottleneck, particularly for DNA/RNA strand production exceeding 100-mers, constraining throughput expansion across the Oligonucleotide Synthesis Market.

## Opportunities

## Oligonucleotide Synthesis Market Opportunities

### Enzymatic Synthesis Disruption for Point-of-Care Applications

For hospital molecular labs and point-of-care diagnostic facilities, benchtop enzymatic synthesizers around USD 150,000 could democratize on-site bespoke oligo synthesis, opening a market that is presently exclusively served by centralized CDMOs On-demand primer manufacture has been successfully piloted by early adopters in translational clinical research labs, reducing turnaround times from days to hours and proving the viability of decentralized diagnostic infrastructure [[11]](https://www.nuclera.com).

### Asia-Pacific Capacity Buildout

China's National Medical Products Administration streamlined GMP inspections for oligonucleotide facilities in 2024, while Indian CDMOs like Biocon and Laurus Labs signaled entry into nucleic acid chemistry synthesis contract services The region's lower labor costs and expanding biosimilar infrastructure position Asia-Pacific as a high-growth manufacturing hub for the Oligonucleotide Synthesis Market over the next decade [[6]](https://www.genscript.com/investor-relations).

### Data Monetization Through Synthesis-as-a-Service Platforms

Subscription-based business models where clients pay per base instead of per instrument are made possible by cloud-connected synthesizers that log sequence data, yield metrics, and process parameters By synthesizing hundreds of thousands of custom oligos at once, Twist Bioscience's digital e-commerce and silicon-based synthesis platform manages enormous throughput. This scalable framework is being actively copied by rivals to generate recurring revenue from DNA/RNA strand production workflows [[18]](https://www.twistbioscience.com/investors).

### mRNA Vaccine and Therapeutic Expansion

Post-pandemic investment in mRNA technology extends well beyond infectious disease: oncology, rare disease, and autoimmune programs require long RNA sequences synthesized under cGMP conditions. The [mRNA therapeutics](https://www.marketresearchfuture.com/reports/mrna-vaccines-therapeutic-market-43671) pipeline exceeded 200 active clinical trials by mid-2024, each consuming CRISPR guide RNA production reagents and modified nucleotides that feed directly into the Oligonucleotide Synthesis Market demand [[12]](https://clinicaltrials.gov).

### Sustainable Chemistry and Green Synthesis

Environmental regulations targeting PFAS and acetonitrile waste streams are driving investment in aqueous-phase and enzymatic alternatives that reduce solvent use by up to 90% [[10]](https://echa.europa.eu). Companies that commercialize green nucleic acid chemistry synthesis processes stand to capture regulatory premium pricing and preferred-vendor status with ESG-conscious pharmaceutical buyers

## Future Outlook

## Oligonucleotide Synthesis Market Future Outlook

### AI-Accelerated Sequence Design and Synthesis Optimization

Machine-learning algorithms are compressing oligo design cycles from weeks to hours by predicting optimal sequences, modification patterns, and coupling conditions before a single base is synthesized. DeepMind's AlphaFold-adjacent nucleic acid structure models and proprietary tools from Twist Bioscience are already reducing design-to-order timelines by 40%, directly boosting throughput across the Oligonucleotide Synthesis Market [[21]](https://www.deepmind.com/research).

### Platform Economics and Synthesis-as-a-Service

The shift from capital-intensive instrument ownership to per-base subscription pricing mirrors the broader SaaS transformation in life sciences. By 2030, MARKET RESEARCH FUTURE (MRFR) projects that over 35% of research-grade DNA/RNA strand production will flow through cloud-connected, automated platforms that bundle synthesis, quality control, and delivery logistics into a single digital workflow, reshaping custom oligo manufacturing economics [[18]](https://www.twistbioscience.com/investors).

### Therapeutic Oligonucleotide Industrialization

As the antisense oligonucleotide therapy and siRNA clinical pipeline expands beyond rare diseases into cardiometabolic and oncology indications, the Oligonucleotide Synthesis Market must evolve from batch-mode to continuous-flow GMP manufacturing. MARKET RESEARCH FUTURE (MRFR) estimates that continuous-flow oligo production could reduce per-gram costs by 50–60% by 2032, unlocking blockbuster-scale nucleic acid drug commercialization [[8]](https://www.alnylam.com/pipeline)[[14]](https://www.avecia.com).

### ESG-Driven Green Chemistry Transition

Environmental pressure on acetonitrile, dichloromethane, and PFAS-containing reagents is accelerating the adoption of aqueous-phase and enzymatic nucleic acid chemistry synthesis methods. The EU's REACH regulation expansion, combined with pharmaceutical industry Scope 3 emissions targets, will make green synthesis capability a procurement prerequisite for CDMOs serving European and North American Oligonucleotide Synthesis Market buyers by 2028 [[10]](https://echa.europa.eu)[[13]](https://research-and-innovation.ec.europa.eu).

## Segment Insights

## Oligonucleotide Synthesis Market Segmentation

### By Product Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Services | ~38% share (2025) | Pharma outsourcing, CDMO expansion |
| Synthesized Oligonucleotide Products | 13.1% CAGR (2026–2035) | Therapeutic-grade oligo demand |
| Reagents & Consumables | USD 0.72 Billion (2025) | Research-grade primer and probe supply |

The Oligonucleotide Synthesis Market services segment reflects the pharmaceutical industry's preference for outsourcing complex nucleic acid chemistry synthesis to specialized CDMOs rather than building in-house capacity. Companies like Ajinomoto Bio-Pharma and Agilent Technologies command premium pricing for GMP-certified custom oligo manufacturing, particularly for antisense oligonucleotide therapy candidates requiring multi-kilogram production runs [[6]](https://www.genscript.com/investor-relations)[[14]](https://www.avecia.com). Synthesized oligonucleotide products — including probes, primers, and therapeutic intermediates — are growing fastest as direct procurement of ready-to-use oligos replaces in-house synthesis at smaller research institutions.

### By Chemistry

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| DNA | ~40% share (2025) | PCR primers, sequencing adapters, gene fragments |
| RNA | 14.2% CAGR (2026–2035) | mRNA therapeutics, CRISPR guide RNA production |
| Modified Chemistries (LNA, PNA, etc.) | USD 0.55 Billion (2025) | Antisense oligonucleotide therapy stability |

DNA/RNA strand production for research applications remains the volume backbone of the Oligonucleotide Synthesis Market, with PCR primers and [next-generation sequencing](https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354) adapters accounting for the majority of DNA oligo orders. RNA synthesis is the fastest-growing chemistry segment, propelled by the mRNA vaccine platform buildout and expanding CRISPR guide RNA production needs across preclinical and clinical programs [[7]](https://www.nature.com/nbt)[[12]](https://clinicaltrials.gov).

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Research | ~49% share (2025) | Academic and industrial R&D volumes |
| Therapeutics | 15.3% CAGR (2026–2035) | Nucleic acid drug approvals |
| Diagnostics | USD 0.57 Billion (2025) | Molecular testing, companion diagnostics |

Research applications dominate the Oligonucleotide Synthesis Market by volume, but therapeutic applications are capturing an outsized share of revenue growth. Clinical-grade oligo manufacturing commands 15–20× the per-base pricing of research-grade equivalents, and the accelerating antisense oligonucleotide therapy and siRNA approval pipeline is expanding this premium segment at nearly double the market-average CAGR [[3]](https://www.liebertpub.com/journal/nat)[[8]](https://www.alnylam.com/pipeline).

### By End-User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Academic Research Institutes | ~68% of order volume (2025) | Government grants, discovery research |
| Pharmaceutical & Biotechnology Companies | 14.6% CAGR (2026–2035) | Clinical-grade custom oligo manufacturing |
| Diagnostic Companies | USD 0.29 Billion (2025) | Probe and primer kit production |

Academic institutes generate the highest order volume in the Oligonucleotide Synthesis Market, though individual order values tend to be modest. Pharma and biotech companies deliver the highest revenue per customer through multi-year CDMO contracts for nucleic acid chemistry synthesis at therapeutic scale, and their share of total market value continues to rise as more antisense oligonucleotide therapy candidates advance through clinical trials [[6]](https://www.genscript.com/investor-relations)[[8]](https://www.alnylam.com/pipeline).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | ~39% share (2025) | Biopharma R&D, FDA fast-tracks, CDMO consolidation |
| Europe | ~27% share (2025) | EMA regulatory clarity, Horizon Europe grants |
| Asia-Pacific | 13.8% CAGR (2026–2035) | Chinese biotech funding, Indian CDMO expansion |
| South America | USD 0.17 Billion (2025) | Diagnostic probe demand, agricultural genomics |
| Middle East & Africa | USD 0.09 Billion (2025) | Genomics center buildout, Saudi Vision 2030 |
| Total | USD 4.10 Billion (2025) | — |

The Oligonucleotide Synthesis Market exhibits distinct regional dynamics, with North America leading in innovation spend, Asia-Pacific accelerating on capacity investment, and Europe anchoring regulatory-grade custom oligo manufacturing.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | ~82% of regional revenue | NIH grants, the largest antisense oligonucleotide therapy pipeline |
| Canada | 10.5% CAGR | Genomics Canada investment, academic research hubs |
| Mexico | USD 0.04 Billion (2025) | Nearshoring of diagnostics manufacturing |

The United States drives four-fifths of North American demand through its unmatched concentration of oligonucleotide drug developers, CDMOs, and federal research funding. The NIH's USD 16.4 million RNA-focused program and BARDA's pandemic preparedness stockpiling contracts underpin stable procurement volumes, while California and Massachusetts biotech clusters generate the bulk of custom oligo manufacturing purchase orders in the Oligonucleotide Synthesis Market [[2]](https://www.nih.gov)[[6]](https://www.genscript.com/investor-relations).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | ~24% of regional share | BioNTech ecosystem, Fraunhofer institutes |
| UK | 12.1% CAGR | NHS Genomic Medicine, enzymatic synthesis pilots |
| France | ~16% of regional share | Sanofi RNA hub, Institut Pasteur programs |
| Italy | USD 0.08 Billion (2025) | Rare-disease therapy development |
| Spain | 11.4% CAGR | Genomics R&D expansion |
| Nordic Countries | ~9% of regional share | Academic oligo research excellence |
| Russia | USD 0.03 Billion (2025) | Domestic self-sufficiency programs |
| Rest of Europe | ~12% of regional share | Varied research and diagnostic demand |

Europe's Oligonucleotide Synthesis Market benefits from Horizon Europe's EUR 120 million nucleic acid research allocation and the EMA's progressive approval framework for antisense oligonucleotide therapy candidates. Germany's BioNTech-anchored ecosystem and the UK's NHS genomic medicine initiative drive the highest per-capita DNA/RNA strand production demand on the continent [[13]](https://research-and-innovation.ec.europa.eu)[[11]](https://www.nuclera.com).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | ~46% of regional revenue | USD 4.3 B biotech funding, GenScript/Suzhou hubs |
| India | 15.2% CAGR | CDMO expansion, affordable custom oligo manufacturing |
| Japan | ~18% of regional share | Precision medicine programs, Takeda pipeline |
| South Korea | 13.6% CAGR | Samsung Biologics entry, K-Bio initiatives |
| ASEAN | USD 0.06 Billion (2025) | Molecular diagnostics adoption |
| Rest of Asia-Pacific | ~5% of regional share | Emerging research institutions |

China's massive biotech funding rounds — exceeding USD 4.3 billion in 2023–2024 alone — and the emergence of domestic champions like GenScript and RiboBio are reshaping Asia-Pacific's role in the Oligonucleotide Synthesis Market from buyer to producer [[6]](https://www.genscript.com/investor-relations). India's Laurus Labs and Biocon are pivoting existing CDMO infrastructure toward nucleic acid chemistry synthesis, targeting antisense oligonucleotide therapy contract manufacturing at 30–40% lower cost than Western providers [[16]](https://www.ibef.org).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | ~58% of regional revenue | FAPESP genomics grants, Butantan Institute |
| Argentina | 10.8% CAGR | Agricultural genomics probes |
| Rest of South America | ~19% of regional share | Diagnostic reagent imports |

Brazil anchors South American demand through its FAPESP-funded genomics programs and the Butantan Institute's expanding role in vaccine-related CRISPR guide RNA production research. Market maturity remains low, and most DNA/RNA strand production reagents are still imported, presenting localization opportunities for the Oligonucleotide Synthesis Market [[19]](https://www.fapesp.br).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | ~34% of regional share | Vision 2030 biotech investment |
| UAE | 12.6% CAGR | Dubai Healthcare City, genomics labs |
| South Africa | ~21% of regional share | Academic research, HIV diagnostics |
| Egypt | USD 0.007 Billion (2025) | Nascent molecular testing infrastructure |
| Rest of MEA | ~22% of regional share | Varied diagnostic demand |

Saudi Arabia's Vision 2030 biotech pillar and the UAE's Dubai Healthcare City are catalyzing genomics lab buildouts that create new import channels for custom oligo manufacturing reagents. South Africa's established academic infrastructure and HIV molecular diagnostics programs sustain the region's highest per-capita consumption within the Oligonucleotide Synthesis Market [[20]](https://www.moh.gov.sa).

## Competitive Benchmarking

## Competitive Benchmarking

The Oligonucleotide Synthesis Market operates at moderate-to-high concentration, with the top five players capturing an estimated 45–52% of global revenue. The Herfindahl-Hirschman Index sits in the 900–1,200 range, reflecting a market that is consolidating around full-service CDMOs and integrated platform companies but retains meaningful participation from specialized niche providers. M&A activity intensified in 2023–2024 as larger players acquired enzymatic synthesis startups and regional contract manufacturers.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Thermo Fisher Scientific | ~10–14% | Custom oligo manufacturing, GMP synthesis, reagents | Full-spectrum platform leader |
| Agilent Technologies | ~8–11% | Therapeutic-grade oligos, SurePrint arrays | High-purity clinical focus |
| Integrated DNA Technologies (IDT) | ~7–10% | Research oligos, gBlocks, PrimeTime probes | Volume research leader |
| Eurofins Genomics | ~5–8% | Custom DNA/RNA strand production, sequencing | European market anchor |
| GenScript Biotech | ~5–7% | Gene synthesis, oligo pools, ClonExpress | Asia-Pacific expansion leader |
| LGC Biosearch Technologies | ~4–6% | Therapeutic oligos, dual-labeled probes | Antisense oligonucleotide therapy CDMO |
| Twist Bioscience | ~3–5% | Silicon-based synthesis, Oligo Pools | Technology disruptor |
| Ajinomoto Bio-Pharma | ~3–5% | GMP oligo CDMO services | Pharma outsourcing specialist |
| Bio-Synthesis Inc. | ~2–4% | Modified oligos, nucleic acid chemistry synthesis | Niche modification expert |
| Nitto Denko Avecia | ~2–4% | Large-scale GMP oligonucleotide production | Industrial-scale CDMO |

## Recent News & Developments

## Recent News & Developments

- [Thermo Fisher Scientific](https://www.thermofisher.com/in/en/home/life-science/oligonucleotides-primers-probes-genes/custom-dna-oligos/asr-gmp-oligonucleotides.html) (March 2025): Opened a USD 200 million oligonucleotide GMP manufacturing facility in Carlsbad, California, doubling its custom oligo manufacturing capacity for the Oligonucleotide Synthesis Market [[4]](https://www.thermofisher.com/investors).
- FDA (August 2024): Granted accelerated approval to a fourth nucleic-acid therapeutic in 2024, reinforcing the regulatory tailwind for the Oligonucleotide Synthesis Market [[3]](https://www.liebertpub.com/journal/nat).
- DNA Script (May 2024): Closed a USD 165 million Series D to scale enzymatic synthesis instruments for benchtop CRISPR guide RNA production and diagnostic probe manufacturing [[11]](https://www.nuclera.com).
- Nitto Denko Avecia (February 2024): Expanded its Manchester, UK, facility with a GBP 60 million investment to triple large-scale therapeutic oligo output [[14]](https://www.avecia.com).
- European Commission (December 2023): Announced EUR 120 million in Horizon Europe funding for nucleic acid research and manufacturing infrastructure across the EU [[13]](https://research-and-innovation.ec.europa.eu).

## Report Scope

## Oligonucleotide Synthesis Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Oligonucleotide Synthesis Market covering products, services, reagents, and CDMO contracts |
| Study Period | 2021–2035 |
| CAGR | 11.32% (2026–2035) |
| Market Size (2025) | USD 4.10 Billion |
| Market Size (2035) | USD 12.68 Billion |
| Fastest Growing Segment | RNA chemistry (by type); Therapeutics (by application); Asia-Pacific (by region) |
| Companies Profiled | 10 (Thermo Fisher, Agilent, IDT, Eurofins, GenScript, LGC Biosearch, Twist, Ajinomoto, Bio-Synthesis, Nitto Denko Avecia) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do enzymatic synthesis platforms compare with phosphoramidite chemistry on per-base cost?**
A: Enzymatic platforms currently run 2–3× higher per base than phosphoramidite for short oligos under 60-mers, but the cost gap narrows sharply for sequences above 150-mers, where chemical coupling efficiency drops [5]. Volume production and next-generation enzyme engineering should bring enzymatic costs to parity by 2029.

**Q: What quality certifications should buyers require from an oligo CDMO?**
A: Buyers should insist on ISO 13485 for diagnostic-grade and FDA 21 CFR Part 211 compliance for therapeutic-grade custom oligo manufacturing [17]. Third-party audit reports and batch-level certificate of analysis documentation are essential procurement safeguards.

**Q: Which antisense oligonucleotide therapy indications offer the largest near-term synthesis volume?**
A: Spinal muscular atrophy and hereditary transthyretin amyloidosis programs drive the bulk of current GMP oligo demand, collectively consuming an estimated 400+ kilograms annually [8]. Cardiometabolic indications entering Phase III will add significant volume by 2028.

**Q: How does the CRISPR guide RNA production scale differ from standard research oligo orders?**
A: CRISPR screening campaigns require 10,000–100,000 unique guide sequences per project, each at microgram scale, making pooled array-based nucleic acid chemistry synthesis the preferred method [7]. Clinical candidates then shift to single-sequence GMP production at the gram scale.

**Q: What procurement strategies reduce lead-time risk in the Oligonucleotide Synthesis Market?**
A: Dual-sourcing across geographies — pairing a North American CDMO with an Asia-Pacific provider — hedges against single-point disruptions [6]. Framework agreements with guaranteed capacity reservations reduce lead times from 8–12 weeks to under 4 weeks.

**Q: How are environmental regulations reshaping the Oligonucleotide Synthesis Market supply chain?**
A: The EU's expanded REACH restrictions on PFAS and acetonitrile waste are forcing CDMOs to invest in solvent-recovery systems or pivot to enzymatic DNA/RNA strand production methods [10]. Facilities that cannot demonstrate green chemistry compliance risk losing European procurement contracts.

**Q: What role does AI play in reducing nucleic acid chemistry synthesis error rates?**
A: Machine-learning models now predict coupling failure hotspots and optimize cycle parameters in real time, cutting truncation errors by up to 30% on sequences above 100-mers [21]. These AI tools also accelerate CRISPR guide RNA production design by screening millions of candidate sequences in hours.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/oligonucleotide-synthesis-market-2337*